KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Raw Materials (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Raw Materials for 9 consecutive years, with $6.1 million as the latest value for Q3 2025.

  • Quarterly Raw Materials rose 68.93% to $6.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $6.1 million through Sep 2025, up 68.93% year-over-year, with the annual reading at $6.7 million for FY2024, 11.26% down from the prior year.
  • Raw Materials hit $6.1 million in Q3 2025 for Bionano Genomics, down from $6.4 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $8.9 million in Q2 2024 to a low of $837000.0 in Q2 2022.
  • Historically, Raw Materials has averaged $5.0 million across 5 years, with a median of $5.8 million in 2023.
  • Biggest five-year swings in Raw Materials: tumbled 60.95% in 2021 and later surged 641.22% in 2023.
  • Year by year, Raw Materials stood at $4.6 million in 2021, then grew by 14.41% to $5.3 million in 2022, then surged by 42.26% to $7.6 million in 2023, then dropped by 11.26% to $6.7 million in 2024, then dropped by 9.41% to $6.1 million in 2025.
  • Business Quant data shows Raw Materials for BNGO at $6.1 million in Q3 2025, $6.4 million in Q2 2025, and $6.6 million in Q1 2025.